Coronavirus Funding Opportunity Announcements

Released by the GCO 7/5 - 7/28/2020

- Coronavirus (7/5/20)
- Coronavirus (7/8/20)
- Coronavirus (7/12/20)
- Coronavirus (7/14/20)
- Coronavirus (7/15/20)
- Coronavirus (7/19/20)
- Coronavirus (7/22/20)
- Coronavirus (7/26/20)
- Coronavirus (7/28/20)
Dear Research Community,

Below are COVID-19 funding opportunities recently released from the NIH and the funding opportunity database SPIN. The NIH Table of Contents is excerpted below followed by funding opportunities from SPIN.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on GCO's Funding Opportunities page and on the ORS Research Roadmap COVID-19 Funding Opportunities page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in The Conduit newsletter.

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

The Grants and Contracts Office

From: Table of Contents for the NIH Guide for Grants & Contracts On Behalf Of Guide TOC
Sent: Thursday, July 2, 2020 3:00 PM
To: NIHTOC-L@LIST.NIH.GOV
Subject: NIH Funding Opportunities and Notices for 07-03-2020 (The NIH Guide TOC)

USE CAUTION: External Message.

Weekly NIH Funding Opportunities and Notices for July 3, 2020

Notices of Special Interest

- **Notice of Special Interest (NOSI): Utilizing Telemedicine or Other Remote-Based Platforms to Develop and Support Treatments for Substance Use Disorders**
  (NOT-DA-20-058) National Institute on Drug Abuse

NIH Funding Opportunities now available in RSS (Really Simple News Syndication) format - see [https://grants.nih.gov/grants/guide/rss_info.htm](https://grants.nih.gov/grants/guide/rss_info.htm) for details.

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>096650</td>
<td>Pre-Studies for Innovation Projects in the Health Area that Prevent Future Pandemics</td>
<td>VINNOVA</td>
<td>18-Aug-2020</td>
<td>100,000 USD</td>
</tr>
<tr>
<td></td>
<td>Contact Name</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email</td>
<td><a href="mailto:covid19utlysning@vinnova.se">covid19utlysning@vinnova.se</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website</td>
<td>Link to sponsor website</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deadline Dates (ALL)</td>
<td>18-Aug-2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis</td>
<td>Vinnova is accepting proposals for health-related innovation projects and feasibility studies that will help to curb the spread and effects of the COVID-19 pandemic and prevent future pandemics.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| 096669  | RSVP Competition                                                              | Corporation for National and Community Service | CNCS-07-01-20 01-Sep-2020 | 518,000 USD |
|         | Contact Name                                                                  | Corporation for National and Community Service | CNCS-07-01-20 01-Sep-2020 | 518,000 USD |
|         | Contact Telephone                                                             | Corporation for National and Community Service | CNCS-07-01-20 01-Sep-2020 | 518,000 USD |
Contact Email 2021RSVP@cns.gov
Sponsor Website Link to sponsor website
Program URL Link to program URL
Deadline Dates (ALL) 01-Sep-2020

The mission of CNCS is to improve lives, strengthen communities, and foster civic engagement through service and volunteering. Through AmeriCorps, Senior Corps, and the Volunteer Generation Fund, CNCS has helped to engage millions of citizens in meeting community and national challenges through service and volunteer action. Grants will help individuals and communities prepare for, respond to, recover from, and mitigate disasters and increase community resiliency. Activities may include assisting in disaster preparedness, response, recovery, and/or mitigation.

Synopsis

Improving Clinical and Public Health Outcomes through National Partnerships to Prevent and Control Emerging and Re-Emerging Infectious Disease Threats

National Center for Emerging and Zoonotic Infectious Diseases/CDC/DHHS2003

14-Jul-2020

[Optional] 5,000,000 USD [LOI/Pre-App]

Contact Name Shanda Blue, Project Officer
Contact Telephone 404-639-1709
Contact Email RFA-CK20-2003@cdc.gov
Sponsor Website Link to program URL
Program URL Link to program URL
Deadline Dates (ALL) 14-Jul-2020 [Optional][LOI/Pre-App], 31-Jul-2020

Through this Notice of Funding Opportunity (NOFO), CDC will continue to protect America from health, safety and security threats, both foreign and in the U.S. This NOFO supports NCEZID’s strategic priorities to prevent the spread of infectious disease. This NOFO is intended to establish a roster of organizations that would be pre-identified and pre-approved for rapid funding to address emerging and re-emerging infectious disease threats through the program strategies. Organizations should have the capacity to reach frontline personnel to inform the development, adaptation, and use of guidance for infectious disease prevention and control. The organizations include, but is not limited to clinicians, other healthcare professionals, healthcare systems, and other organizations and institutions responsible for patient care and infectious disease prevention and control in the United States. This NOFO will establish an Approved-But-Unfunded (ABU) list of recipients, which will be used to effectively respond to public health threats. There is limited funding available at the time of this announcement. Additional funding will be contingent upon the availability of appropriations, at CDC’s sole discretion. CDC will provide additional information to ABU recipients, as public health needs arise.

Synopsis
SMARTSTM funding alerts are a service of InfoEd Global’s SPINSTM funding opportunities

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.
This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

Visit the Research Portal Getting Started page and enter email address under Research Listserv to update your subscription preferences at any time within the MSHS firewall.
Dear Research Community,

Below are COVID-19 funding opportunities recently released from the funding opportunity database SPIN. The first table is a summary followed by a second with more detailed information.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on GCO’s Funding Opportunities page and on the ORS Research Roadmap COVID-19 Funding Opportunities page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in The Conduit newsletter.

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

The Grants and Contracts Office

### SPIN Table 1 - Summary

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>004510</td>
<td>Incentive Grants for Residents and their Preceptors</td>
<td>American Pharmacists</td>
<td></td>
<td>08-Sep-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td></td>
<td>Systems for Action:</td>
<td>Association Foundation</td>
<td></td>
<td>20-Jul-2020</td>
<td></td>
</tr>
</tbody>
</table>
Supplemental Research on COVID-19 Response and Recovery

Notice of Special Interest (NOSI): Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 Diseases/NIH/DHHS (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)


CDC COVID-19 Health Policy Fellowship

SARS-CoV-2 and Cystic Fibrosis Research Award Foundation

COVID-19 RFP Program: COMMIT

Just Tech Covid-19 Rapid-Response Grants

**SPIN Table 2 - Detailed Information**

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>004510</td>
<td>Incentive Grants for Residents and their Preceptors</td>
<td>American Pharmacists Association Foundation</td>
<td></td>
<td>08-Sep-2020</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>
Contact Name: John Little, Executive Fellow  
Contact Telephone: 202-558-2709  
Contact Email: jlittle@aphanet.org  
Sponsor Website: Link to sponsor website  
Program URL: Link to program URL  

The sponsor offers grants totaling more than $500,000, which has facilitated the development of over 500 pharmacy-based projects, improving the health outcomes of thousands of patients across the United States. These incentive grants offer pharmacists, students, and community pharmacy residents seed money to implement or support an existing innovative patient care service within their pharmacy practice. Incentive Grants are awarded annually on a calendar year. Grant recipients will be required to submit an interim report, a final project report, a final project expense report, and a short video summary of their project. Added in 2020, grants will also be offered with a focus on COVID-19 prevention, treatment, and testing.

Synopsis

20-Jul-2020 [Optional] [LOI/Pre-App] Not Specified

Contact Name  
Contact Telephone: 303-724-3759  
Contact Email: systemsforaction@ucdenver.edu  
Sponsor Website: Link to sponsor website  
Program URL: Link to program URL  
Deadline Dates (ALL): 20-Jul-2020 [Optional][LOI/Pre-App], 05-Aug-2020

Systems for Action (S4A) is a signature research program of the Robert Wood Johnson Foundation that helps to build the evidence base for a Culture of Health by rigorously testing new ways of connecting the nation’s fragmented medical, social, and public health systems. This call for proposals (CFP) will provide supplemental research funding to teams that are already engaged in the study of a promising system alignment mechanism, with the objective of learning how this mechanism performs in addressing health and social needs during the COVID-19 pandemic. Applicants responding to this CFP may apply for awards of 12 months or 24 months in duration and up to $100,000 per year in total costs to support supplemental studies that evaluate the implementation and impact of a system alignment mechanism in the context of the COVID-19 pandemic.

Synopsis

Notice of Special Interest (NOSI): Emergency Competitive Revisions for Select Research National Institute of
Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

Contact Name Diane Post, Ph.D.
Contact Telephone 240-627-3348
Contact Email postd@niaid.nih.gov
Sponsor Website
Program URL Link to program URL
Deadline Dates (ALL) 02-Jul-2021
Synopsis
NIAID is issuing this Notice of Special Interest (NOSI) to highlight very specific and limited needs for Competitive Revision applications to active NIAID grants in order to further build the infrastructure that NIAID needs to support the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) research response. This NOSI replaces NOT-AI-20-034 which was rescinded with this issuance of this Notice.


Contact Name
Contact Telephone
Contact Email
Sponsor Website
Program URL Link to program URL
Deadline Dates (ALL) 14-Aug-2020
Synopsis
Through this Notice of Special Interest (NOSI), the National Cancer Institute (NCI) announces an opportunity for current NCI funded Principal Investigators whose postdoctoral fellows have temporarily lost stipend support from a non-profit funder because of the COVID-19 global pandemic may apply for an administrative supplement to cover the postdoctoral fellow’s salary plus applicable F&A for the time and effort devoted to the NCI funded grant.
Six research opportunities are currently available with the Division of Birth Defects and Infant Disorders (DBDID) of the National Center for Birth Defects and Developmental Disabilities (NCBDDD) at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia.

The Cystic Fibrosis Foundation is requesting Letters of Intent (LOIs) for basic science research projects that aim to improve our understanding of SARS-CoV-2 pathogenesis in cystic fibrosis. As the COVID-19 pandemic evolves, additional data will become available to shed light on populations that may have an increased susceptibility for contracting the disease as well as those who may experience a range in illness severity associated with this virus.

In an effort to further address the unmet medical need in COVID-19, Gilead Medical Affairs is launching the COMMIT program. The COMMIT program will support well defined individual projects.
The Social Science Research Council (SSRC), as part of its Just Tech program, seeks proposals from across the social sciences and related fields that address the risks, opportunities, and challenges posed by public health surveillance stemming from the Covid-19 pandemic. The sponsor specifically encourages proposals that interrogate the role the public and private sectors may play in mitigating or exacerbating the health crisis, the effects of which are already unevenly distributed.
Dear Research Community,

Below are COVID-19 funding opportunities recently released from the NIH and the funding opportunity database SPIN.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on GCO's Funding Opportunities page and on the ORS Research Roadmap COVID-19 Funding Opportunities page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in The Conduit newsletter.

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

The Grants and Contracts Office

From: Table of Contents for the NIH Guide for Grants & Contracts On Behalf Of Guide TOC
Sent: Friday, July 10, 2020 3:02 PM
To: NIHTOC-L@LIST.NIH.GOV
Subject: NIH Funding Opportunities and Notices for 07-10-2020 (The NIH Guide TOC)
NIH Guide for Grants and Contracts (Web Version)

Weekly NIH Funding Opportunities and Notices for July 10, 2020

General Notices

- Notice of Early Expiration of "Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)" (NOT-AI-20-058) National Institute of Allergy and Infectious Diseases

- Request for Information (RFI): Seeking Stakeholder Input on Scientific Gaps and Research Needs Related to Delivery of Cancer-related Care via Telehealth (NOT-CA-20-080) National Cancer Institute

Notice of Changes to Funding Opportunities

- Notice of Clarification to Key Dates for RFA-CA-20-039 "Emergency Awards: Research Projects in SARS-CoV-2 Serological Sciences (U01 Clinical Trial Optional)" (NOT-CA-20-076) National Cancer Institute

Funding Opportunities

- Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required) (RFA-DK-20-011) National Institute of Diabetes and Digestive and Kidney Diseases Application Receipt Date(s): November 4, 2020

- Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required) (RFA-DK-20-012) National Institute of Diabetes and Digestive and Kidney Diseases Application Receipt Date(s): November 4, 2020

- Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional) (RFA-DK-20-021) National Institute of Diabetes and Digestive and Kidney Diseases Application Receipt Date(s): December 16, 2020

NIH Funding Opportunities now available in RSS (Really Simple News Syndication) format -
see [https://grants.nih.gov/grants/guide/rss_info.htm](https://grants.nih.gov/grants/guide/rss_info.htm) for details.

### SPIN ID Program Title

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>096827</td>
<td>TD Ready Challenge</td>
<td>TD Banknorth Charitable Foundation</td>
<td></td>
<td>13-Aug-2020</td>
<td>730,000 USD</td>
</tr>
</tbody>
</table>

**Synopsis**

The TD Ready Challenge is an annual North American initiative, which supports organizations developing innovative solutions for a changing world. Recipients must be organizations that have impactful and measurable solutions focused on helping to open doors for a more inclusive and sustainable tomorrow. The COVID-19 pandemic has had an immense impact on society and that's why this year, the sponsor has made the decision to focus the 2020 TD Ready Challenge on supporting innovative solutions that address the impacts of the pandemic.

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Deadline Dates (ALL)</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>096845</td>
<td>Health Equity Innovations Fund</td>
<td>Genentech</td>
<td>10-Aug-2020 [LOI/Pre-App], 05-Oct-2020</td>
<td>750,000 USD</td>
</tr>
</tbody>
</table>

**Synopsis**

This call for grant proposals will support action-oriented research, demonstration projects, and programs to build the evidence base needed to promote health equity and reduce disparities in healthcare access, quality, and outcomes amongst populations facing the greatest needs - particularly communities of color. Funded proposals will develop, test, and/or scale strategies and interventions that reduce disparities and promote health equity. Successful proposals will also
support health systems and hospitals, practitioners, advocates, community leaders, patients and caregivers, and decision-makers in setting priorities and allocating resources towards solutions that improve the health and wellbeing of historically underserved patients within Genentech’s disease areas of focus. Research projects must be U.S. based.

RFP -- Idaho National Laboratory COVID-19 Technical Assistance Program

Department of Energy C-TAP 08-Sep-2020 Not Specified

Contact Name
Contact Telephone
Contact Email td@inl.gov
Sponsor Website
Program URL Link to program URL
Deadline Dates (ALL) 08-Sep-2020

The Department of Energy's Office of Technology Transitions has announced new resources for innovators to combat COVID-19 through the COVID-19 Technical Assistance Program (CTAP). CTAP will provide targeted funding to DOE's national laboratory system to assist non-DOE entities working to combat the coronavirus pandemic. CTAP is designed to allow external entities – including state, tribal and local governments; regional and local businesses; and other private sector entities – to engage directly with DOE lab researchers. These groups would be enabled to tap researchers' technical expertise to work through and overcome difficult technical or scientific challenges related to combating the novel coronavirus. Funding provided under this program will cover up to 40 hours of consultation with INL staff. Work anticipated for CTAP projects is not R&D intensive, leverages INL's unique capabilities or expertise and should not be intended to generate intellectual property. Only projects that provide COVID-19-related technical assistance to U.S. entities will be considered. Interested entities should provide: An technical representative at INL that will be the principle investigator that will work with you; Name and address of external entity requesting CTAP; The name of the representative that is your contact for your entity; Proposed project description, must include explanation of potential impact to work related to a COVID-19 response; Proposed funding request (funding request should be relatively small – e.g. 40 hours or $5,000) Funding decisions are made as proposals are received, based on available funding. Entities that may be able to take advantage of this program should email td@inl.gov with the above information. More information about INL’s expertise and capabilities can be found at www.inl.gov.

Synopsis

af63e86eb38841b4a89796455f0a4efc Source
https://beta.sam.gov/opp/af63e86eb38841b4a89796455f0a4efc/view
SMARTS™ funding alerts are a service of InfoEd Global's SPIN™ funding opportunities.

Visit the Research Portal Getting Started page and enter email address under Research Listserv to update your subscription preferences at any time within the MSHS firewall.
Dear Research Community,

Below are COVID-19 funding opportunities recently released from the funding opportunity database SPIN.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on GCO's Funding Opportunities page and on the ORS Research Roadmap COVID-19 Funding Opportunities page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in The Conduit newsletter.

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

The Grants and Contracts Office

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>096954</td>
<td>JATF_CSO_COVID_19</td>
<td>Department of the Air Force</td>
<td>FA701320S002</td>
<td>15-Aug-2020</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>

Contact Name: Jessica.Steinhoff
Contact Telephone: jess.steinhoff@afwerx.af.mil
Sponsor Website:
Program URL | [Link to program URL](#)
--- | ---
Deadline Dates (ALL) | 15-Aug-2020

**Synopsis**

This announcement has been reissued to administratively update the solicitation number (previously FA3002-20-S0002) and highlight the CSO's purpose for bolstering industrial capacity for domestic supplier base in support of JATF & HHS COVID-19 response priorities. All pending award determinations submitted under the previous solicitation number remain valid for government review and consideration. This CSO announcement anticipates soliciting solution briefs through separate & periodically published Areas of Interest (AOI) to meet JATF & HHS COVID-19 response priorities; with an emphasis on Strategic National Sourcing strategy that seeks to strengthen direct or tangential domestic supplier sources, increase market resiliency/competition with a goal of bolstering the national industrial capacity for medical, pharmaceutical and/or other personal protective equipment. See attachments for full CSO and corresponding AOIs.

<table>
<thead>
<tr>
<th>COVID 19 – Operational Challenges for Corrections</th>
<th>National Institute of Corrections/Department20PR07</th>
<th>27-Aug-2020</th>
<th>175,000 USD</th>
</tr>
</thead>
</table>

**Contact Name** | Evelyn Bush, Correctional Program Specialist
**Contact Telephone** | 
**Contact Email** | e1bush@bop.gov
**Sponsor Website** | [Link to sponsor website](#)
**Program URL** | 
**Deadline Dates (ALL)** | 27-Aug-2020

**Synopsis**

NIC’s seeking applications for funding under the Fiscal Year (FY) 2020 to support knowledge sharing around the nationwide correctional challenges that prisons, jails, and community services face during the COVID19 pandemic.

SMARTSTM funding alerts are a service of InfoEd Global's SPINTM funding opportunities

---

**PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.**

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

Visit the Research Portal Getting Started page and enter email address under Research Listserv to update your subscription preferences at any time within the MSHS firewall.
Dear Research Community,

Below are COVID-19 funding opportunities recently released from the funding opportunity database SPIN. The first table is a summary followed by a second with more detailed information.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on GCO's Funding Opportunities page and on the ORS Research Roadmap COVID-19 Funding Opportunities page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in The Conduit newsletter.

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

The Grants and Contracts Office

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Deadline Number</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>080304</td>
<td>COVID 19 Response Fund - Support, Connect and Rebuild - Small Grants Program</td>
<td>Tasmanian Community Fund</td>
<td>26-Aug-2020</td>
<td>13,800 USD</td>
</tr>
</tbody>
</table>
COVID 19 Response Fund - Support, Connect and Rebuild - Medium Grants Program

Tasmanian Community Fund 30-Sep-2020 48,300 USD

COVID 19 Response Fund - Support, Connect and Rebuild - Large

Tasmanian Community Fund 12-Aug-2020 345,000 USD
[LOI/Pre-App]

Boosting Frontline Health Workers’ Ability in Responding to COVID-19 - Virtual Awareness and Capacity Building Training Project

Department of State Public Health 10-Aug-2020 40,000 USD

Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed)

National Institute of Allergy and Infectious Diseases/NIH/DHHS Continuous Submission Not Specified

**SPIN Table 2 - Detailed Information**

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Deadline Number</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>080304</td>
<td>COVID 19 Response Fund - Support, Connect and Rebuild - Small Grants Program</td>
<td>Tasmanian Community Fund</td>
<td>26-Aug-2020</td>
<td>13,800 USD</td>
</tr>
</tbody>
</table>

**Contact Name** Cheryl Walker
**Contact Telephone** 6165 8333
**Contact Email** admin@tascomfund.org
**Sponsor Website** [Link to sponsor website](#)
**Program URL** [Link to program URL](#)
**Deadline Dates (ALL)** 26-Aug-2020

The Tasmanian Community Fund will be calling for small, medium and large applications that support Tasmanians and Tasmanian organisations to recover and rebuild from Covid19. The Tasmanian Community Fund aims to support a broad range of projects and organisations. Up to $20,000 is available for small grants.
COVID 19 Response Fund - Support, Connect and Rebuild - Medium Grants  
Tasmanian Community Fund  
30-Sep-2020  
48,300 USD

Contact Name  
Contact Telephone  (03) 6165 8333  
Contact Email  admin@tascomfund.com.au  
Sponsor Website  Link to sponsor website  
Program URL  Link to program URL  
Deadline Dates (ALL)  30-Sep-2020

Synopsis
The Tasmanian Community Fund is committed to making grants to community organisations that make a difference by improving the social, environmental and economic wellbeing of the Tasmanian community. The Tasmanian Community Fund is calling for medium applications that support Tasmanians and Tasmanian organisations to recover and rebuild from Covid19. The TCF is seeking applications across three streams:  
Support - supporting and meeting the needs of vulnerable people to ensure they are not left behind as a result of Covid19;  
Connect - creating spaces and programs/processes to enable individuals and communities to reconnect and rebuild the social fabric of communities;  
Rebuild - providing individual and organisational capacity building including options for realigning work and directions for the “new normal” and beyond.

COVID 19 Response Fund - Support, Connect and Rebuild - Large  
Tasmanian Community Fund  
12-Aug-2020 [LOI/Pre-App]  
345,000 USD

Contact Name  Lola Cowle  
Contact Telephone  03 6165 8333  
Contact Email  admin@tascomfund.org  
Sponsor Website  Link to sponsor website  
Program URL  Link to program URL  
Deadline Dates (ALL)  12-Aug-2020 [LOI/Pre-App], 11-Nov-2020

Synopsis
The Tasmanian Community Fund is calling for stage 1 applications ($100 000 to $500 000) for a range of community infrastructure projects. This year, the Fund calls for large applications that support Tasmanians and Tasmanian organisations to recover and rebuild from Covid19. The TCF is seeking applications across three streams: ??Support – supporting and meeting the needs of vulnerable people to ensure they are not left behind as a result of Covid19 Connect – creating spaces and programs/processes to enable individuals and communities to reconnect and rebuild the social fabric of communities; Rebuild – providing individual and organisational capacity building including options for realigning work and directions for the “new normal” and beyond.
Boosting Frontline Health Workers’ Ability in Responding to COVID-19 - Virtual Awareness and Capacity Building Training Project

Department of State
PAS-CMR-FY20-07
10-Aug-2020
40,000 USD

Contact Name
Contact Telephone
Contact Email PASGrantsYaounde@state.gov
Sponsor Website
Program URL Link to program URL
Deadline Dates (ALL) 10-Aug-2020

Synopsis
The U.S. Embassy in Cameroon announces an open competition for organizations to submit applications to support Cameroon’s COVID-19 response, focusing on increasing awareness, motivating informed and constructive action, supporting frontline medical workers, and/or countering misinformation. Awards may range from $10,000 to $40,000.

Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed)

National Institute of Allergy and Infectious Diseases/NIH/DHHS
PAR-20-256
Continuous Submission Not Specified

Contact Name Dr. Andrea Wurster
Contact Telephone 301-496-7291
Contact Email NIAID_PPE@mail.nih.gov
Sponsor Website
Program URL Link to program URL
Deadline Dates (ALL)

Synopsis
The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by “The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” and “The Coronavirus Aid, Relief and Economic Security (CARES) Act”.

22
SMARTSTM funding alerts are a service of InfoEd Global's SPINTM funding opportunities.

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE. This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

Visit the Research Portal Getting Started page and enter email address under Research Listserv to update your subscription preferences at any time within the MSHS firewall.
Dear Research Community,

Below are COVID-19 funding opportunities recently released from the NIH and the funding opportunity database SPIN.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserve are posted on GCO's Funding Opportunities page and on the ORS Research Roadmap COVID-19 Funding Opportunities page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in The Conduit newsletter.

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

The Grants and Contracts Office
Weekly NIH Funding Opportunities and Notices for July 17, 2020

Notice of Changes to Funding Opportunities

- Notice of Expiration of PAR-20-178 "Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed)" (NOT-AI-20-062) National Institute of Allergy and Infectious Diseases

- Notice of Expiration of PAR-20-177 "Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed)" (NOT-AI-20-063) National Institute of Allergy and Infectious Diseases

NIH Funding Opportunities now available in RSS (Really Simple News Syndication) format - see https://grants.nih.gov/grants/guide/rss_info.htm for details.

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>097080</td>
<td>Pandemic Response and Real Time Food Away from Home Data</td>
<td>Agricultural Research Service/Department of Agriculture</td>
<td>1003692</td>
<td>22-Jul-2020</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>

Contact Name: Marcos A. Ocadiz
Contact Telephone: 301-504-1749
Contact Email: marcos.ocadiz@ars.usda.gov
Sponsor Website: Link to sponsor website
Program URL: Link to program URL
Deadline Dates (ALL) 22-Jul-2020
Solicitation as per attachments. Proposal submissions should be sent via email as per this solicitation. Intended Use and Purpose Accurate, comprehensive, and representative FAFH purchase, consumption, sales data that are collected and delivered at a high frequency are needed to support ongoing research activities conducted by the USDA. This includes providing regular and up-to-date economic intelligence to USDA policymakers and key stakeholders in response to the COVID-19 pandemic. Total impacts of the pandemic on the end of the food supply chain and Americans’ diets comprise changes in FAH purchases, changes in FAFH purchases, and what consumers do with these purchases (e.g., consume, store, waste). Additional data surveying all food consumption behavior, pantry loading behavior, and characteristics of FAFH purchases and sales helps contextualize changes in American’s diets broadly. The USDA will use the data for projects that support economic and policy research that is shared both internally and with the public at large. The research projects are often undertaken in collaboration with external experts, including but not limited to economists, researchers, and survey and data methodologists at non-governmental organizations. For such collaborations, data will be shared with external research collaborators. The data may be used in combination with (linked to) other data to conduct the research projects. The resulting aggregated findings (not the raw data) will be disseminated through multiple media, including but not limited to professional economic journals, USDA publications, the USDA website, and presentations at meetings of professional economics associations. Before public release, all publications and reports will be reviewed by USDA to meet data disclosure requirements and to strictly maintain privacy and confidentiality requirements of data purveyors. The USDA will retain the right to use the data and information indefinitely to undertake its projects as specified above. General Tasks/Requirements The requested data need to have a time frequency of collection that is weekly and, at most, monthly. Delivery should take place on a weekly to monthly to basis, with a time gap between collection and delivery that is as short as one week and, at most, a month if necessary. Data should be delivered for 52 weeks following the execution of the contract. The time coverage should begin in January 2020 at the latest to ensure a sufficient comparison in advance of the changes caused by the pandemic. However, a start state after January 2020 but sufficiently close to March 2020 for data products developed in direct response to the pandemic is acceptable. The data should be representative of FAH and FAFH behavior or market characteristics at the national and regional levels (e.g., Census Region and/or Division). If a facet of the data is not nationally or regionally representative, then the coverage should either (a) crosswalk with other nationally representative facets or (b) provide a sufficiently high proportion of the most important consumer households and/or food service establishments. Base Task 1: Real time data on household-focused data Household consumption data should track the types of food being eaten, where it was acquired, how it was prepared, the nutrition content, and dollars spent that all
includes FAFH consumption. In addition, measures on food consumption should be linkable to select items stored in the home. The household data should be available by key demographic information such as: number of members age of household head or other members presence of children whether children received school lunch income geographic location (Census Region and/or Division). Documentation should provide information on how data are collected, including sampling strategy to ensure representativeness. Support answering questions should be provided within a week, providing updates to data with problematic records. Base Task 2: Real time data on food service establishment focused data Food service establishment sales data should include by key characteristics the share of transactions, change in share of transaction, dollar value of sales, restaurant traffic, number of items per order, and dollar value of orders. The key characteristics include segment (e.g., quick-service, or casual dining) category (e.g., the menu type) meal-type/time of day geographic location (Census Region and/or Division) Task 3 (Option Years) These data may be need for subsequent years. USDA request quotes for 4 additional years, one for each year hence. Period of Performance Base: 52 weeks after the award Base: 52 weeks for each option year Deliverable Schedule Task Deliverable Due Date Task 1, Task 2, and Task # (option years) 1) Real time data on household-focused data; 2) Real time data on food service establishment focused data First delivery will take place 5 business days after award. Each additional delivery will take place weekly to monthly (terms for individual facets to be determined) for 52 weeks thereafter. Additional beta.sam.gov information Notice Id b55dc5ba0e7d4823ab490b89b6e0eae2 Source https://beta.sam.gov/opp/b55dc5ba0e7d4823ab490b89b6e0eae2/view Note: This link might not be valid after archive date below. Archive Date 8/6/2020

**National Survey of Health Information Exchange Organizations (HIO)**

| Contact Name | Erneisha Bailey |
| Contact Telephone | 3014924656 |
| Contact Email | erneisha.bailey@psc.hhs.gov |
| Sponsor Website | Link to sponsor website |
| Program URL | |
| Deadline Dates (ALL) | 05-Aug-2020 |

Description The 21st Century Cures Act (Cures Act), enacted in 2016, has a number of health IT provisions that are being developed and implemented to address various barriers to health information exchange that intersect with health information exchange

27
Health information exchange organizations (HIOs). Health information exchange organizations, which provide both the technical infrastructure and governance to enable exchange, have worked with a diverse set of stakeholders in their communities, whether at the local, state or regional level. A number of studies have found the use of health information exchange organizations (HIOs) is significantly associated with greater exchange and interoperability in hospital settings. Currently, health care providers may have to join multiple networks in order to exchange with their referral partners as limited exchange is occurring across networks. A key aspect of the health IT provisions of the Cures Act is to implement a trusted exchange framework and common agreement that will enable exchange across disparate health information exchange networks. Qualified Health Information Networks (QHINs) shall connect to each other once they join the TEFCA; their participants (including health information exchange organizations) will then be able to share information across participating QHINs. Assessing the early implementation of the TEFCA and its perceived effect on information exchange organizations’ role in facilitate exchange will be important to guiding ONC policy. Another key aspect of the Cures Act is to address information blocking, a practice that “is likely to interfere with, prevent, or materially discourage access, exchange, or use of electronic health information.” According to the Cures Act, health care providers and technology vendors shall be penalized for these actions. While complaints and penalties can be tracked to monitor information blocking, these would likely capture only the most egregious cases. Broader information that captures the types and overall prevalence of information blocking can help guide the implementation of the regulation and assess the impact on the overall market. In a 2015 report to Congress, ONC identified information blocking on the part of vendors or providers as a potential barrier to interoperability. The report noted that there is little information currently available on the extent to which this is occurring; however, that “to fill these gaps, ONC is considering additional sources of data from key entities that enable health information exchange and interoperability, such as health information exchange entities (HIEs), health information service providers (HISPs) and health information technology (IT) developers (p.20).” Health information exchange organizations (HIOs) are in a unique position to share their insights on information blocking as they work closely with both health care providers and technology vendors in facilitating exchange for their community. In addition to implementing health IT provisions of the Cures Act, other key elements aspects of ONC’s work relate to promoting the use of established interoperability standards and implementation specifications to facilitate electronic exchange of health information. ONC updates and maintains the interoperability standards advisory (ISA), which serves as a guide to industry regarding the use of standards to support specific clinical health IT interoperability needs. ONC needs data on how well standards are conforming and used to make updates to its Interoperability Standards.
Advisory. The usage and conformance of standards is another critical area that ONC must measure. Again, given their unique role in working closely with both health care providers and technology vendors, HIOs can provide insights into the implementation and use of standards to facilitate exchange. As noted, HIOs are in a position to provide useful perspectives on ONC’s work related to implementing the health IT provisions of the Cures Act and advancing the use of recognized standards. Additionally, continuing to understand the evolving role of HIOs is critical. Studies published in Health Affairs show that HIOs lack sustainable sources of funding to support the services they provide. Understanding their continued role in advancing exchange and interoperability will be important, as they have demonstrated their value to be a critical enabler of health information exchange and interoperability. For example, HIOs are also providing services to support their communities during the COVID-19 pandemic. Examining these emergent areas is also important. Additional beta.sam.gov information Notice Id d3b459b3589d4122abe70f772063d576 Source https://beta.sam.gov/opp/d3b459b3589d4122abe70f772063d576/view Note: This link might not be valid after archive date below.

SMARTS™ funding alerts are a service of InfoEd Global's SPIN™ funding opportunities
Dear Research Community,

Below are COVID-19 funding opportunities recently released from the funding opportunity database SPIN.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on GCO's Funding Opportunities page and on the ORS Research Roadmap COVID-19 Funding Opportunities page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in The Conduit newsletter.

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

The Grants and Contracts Office

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Deadline</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>097117</td>
<td>Competitive Grant Program: Optimal Early Therapy Management in CML</td>
<td>Pfizer Pharmaceuticals</td>
<td>01-Oct-2020</td>
<td>150,000 USD</td>
</tr>
</tbody>
</table>

Contact Name: Jacqueline Waldrop, Grant Officer
Contact Telephone: 212-733-2323
Contact Email: Jacqueline.Waldrop@pfizer.com
Sponsor Website: Link to sponsor website
Program URL: Link to program URL
Deadline Dates (ALL): 01-Oct-2020
Pfizer Global Medical Grants (GMG) will support three Quality Improvement (QI) Projects that will enhance systems of care or implement new tools that will optimize early therapy management for patients with Chronic Myelogenous Leukemia (CML). The intent of the RFP is to support one project in Canada and two in the United States. Individual projects requesting up to $150,000 will be considered.

**Synopsis**

**Lifespan Respite Care Program: Special Projects to Strengthen Program Development, Implementation and Sustainability**

Contact Name: Lori Stalbaum  
Contact Email: Lori.Stalbaum@acl.hhs.gov  
Sponsor Website: Link to sponsor website  
Program URL: Link to program URL  
Deadline Dates (ALL): 14-Aug-2020 [Optional][LOI/Pre-App], 03-Sep-2020  

The U.S. Administration for Community Living (ACL), Administration on Aging (AoA), will be publishing a competitive grant opportunity to implement special projects under the authority granted in Section 2903 of the Lifespan Respite Care Act of 2006 (P.L. 109-442). These special projects will complement the work of the Lifespan Respite Technical Assistance and Resource Center (TARC). Additionally, under the “RAISE Family Caregivers Act,” an Advisory Council has been established to “provide the establishment and maintenance of a [National] Family Caregiving Strategy…” With the formation of the Family Caregiving Advisory Council and the forthcoming National Strategy, an anticipated focus on improving access to respite, workforce issues, and the role of natural supports will be a likely focus of attention nationwide.

**Synopsis**

**COVID-19 ICU Design Award**

Contact Name: Carol Prendergast  
Contact Telephone: 847-827-6888  
Contact Email: cprendergast@sccm.org  
Sponsor Website: Link to sponsor website  
Program URL: Link to program URL  
Deadline Dates (ALL): 15-Aug-2020  

The COVID-19 ICU Design Award honors a critical care unit that was built or heavily modified from late 2019 through May 2020 to expand ICU bed capacity. The ICU design should be configured to provide care for COVID-19 patients as well as to ensure staff safety.
SMARTSTM funding alerts are a service of InfoEd Global's SPINSTM funding opportunities

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE. This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

Visit the Research Portal Getting Started page and enter email address under Research Listserv to update your subscription preferences at any time within the MSHS firewall.
Dear Research Community,

Below are COVID-19 funding opportunities recently released from the NIH and the funding opportunity database SPIN.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on GCO's Funding Opportunities page and on the ORS Research Roadmap COVID-19 Funding Opportunities page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in The Conduit newsletter.

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

The Grants and Contracts Office
NIH Guide for Grants and Contracts (Web Version)

Weekly NIH Funding Opportunities and Notices for July 24, 2020

Notice of Changes to Funding Opportunities

- **Notice of NHLBI Participation in NOT-OD-20-097 "Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences"**
  (NOT-HL-20-799) National Heart, Lung, and Blood Institute

- **Notice of Expiration of NOT-HL-20-782 "Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions on Coronavirus Disease 2019 (COVID-19) for Currently Active NHLBI Phase I-III Clinical Trials"**
  (NOT-HL-20-800) National Heart, Lung, and Blood Institute

- **Notice of NHLBI Participation in NOT-OD-20-097 "NOSI regarding Availability of Admin Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences**
  (NOT-HL-20-801) National Heart, Lung, and Blood Institute

- **Notice of NHLBI Participation in NOT-OD-20-119 "Notice of Special Interest (NOSI): Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations"**
  (NOT-HL-20-803) National Heart, Lung, and Blood Institute

- **Notice of NHLBI Participation in NOT-OD-20-120 "Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations"**
  (NOT-HL-20-804) National Heart, Lung, and Blood Institute

- **Notice of NHLBI Participation in NOT-OD-20-121 "Notice of Special Interest (NOSI): Limited Competition for Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations"**
  (NOT-HL-20-805) National Heart, Lung, and Blood Institute

NIH Funding Opportunities now available in RSS (Really Simple News Syndication) format - see [https://grants.nih.gov/grants/guide/rss_info.htm](https://grants.nih.gov/grants/guide/rss_info.htm) for details.
<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>097293</td>
<td>Ecology and Evolution of Infectious Diseases</td>
<td>National Science Foundation</td>
<td>20-585</td>
<td>18-Nov-2020</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>

Contact Name          Katharina Dittmar  
Contact Telephone     703-292-7799  
Contact Email         kdittmar@nsf.gov  
Sponsor Website       Link to sponsor website  
Program URL           Link to program URL  
Deadline Dates (ALL)  18-Nov-2020  

The multi-agency Ecology and Evolution of Infectious Diseases program supports research on the ecological, evolutionary, and social drivers that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be the quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of transmission among any host species, including but not limited to humans, non-human animals, and/or plants. This includes, for example, the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of reservoir species or hosts; the feedback between ecological transmission and evolutionary dynamics; and the cultural, social, behavioral, and economic dimensions of pathogen transmission. Research may be on zoonotic, environmentally-borne, vector-borne, or enteric pathogens of either terrestrial or aquatic systems and organisms, including diseases of animals and plants, at any scale from specific pathogens to inclusive environmental systems. Proposals for research on disease systems of public health concern to developing countries are strongly encouraged, as are disease systems of concern in agricultural systems. Investigators are encouraged to develop the appropriate multidisciplinary team, including for example, anthropologists, modelers, ecologists, bioinformaticians, genomics researchers, social scientists, economists, oceanographers, mathematical scientists, epidemiologists, evolutionary biologists, entomologists, parasitologists, microbiologists, bacteriologists, virologists, pathologists or veterinarians, with the goal of integrating knowledge across disciplines to enhance our ability to predict and control infectious diseases.
SMARTSTM funding alerts are a service of InfoEd Global’s SPINTM funding opportunities
Dear Research Community,

Below are COVID-19 funding opportunities recently released from the funding opportunity database SPIN.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on GCO's Funding Opportunities page and on the ORS Research Roadmap COVID-19 Funding Opportunities page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in The Conduit newsletter.

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

The Grants and Contracts Office

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>097324</td>
<td>Domestic Manufacturing Capacity Expansion</td>
<td>Department of the Army</td>
<td>W911QY-20-S-0018</td>
<td>31-Oct-2020</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>

Contact Name: John Conlin
Contact Telephone: john.conlin3.civ@mail.mil
Contact Email: john.conlin3.civ@mail.mil
Sponsor Website: Link to program URL
Program URL: Link to program URL
Deadline Dates (ALL): 31-Oct-2020

The recipient shall expand existing domestic Continental US (CONUS)
Based manufacturing capacity for COVID-19 vaccine consumables products. The recipient shall identify, develop and qualify new U.S.-based manufacturing capacity for utilization with USG (BARDA and affiliate partners) COVID-19 vaccines. Expansion of existing domestic capacity shall be through expansion of manufacturing capabilities in existing and new recipient facilities. Specific Objectives: 1. The recipient shall develop a vaccine consumables manufacturing capacity and production solution to provide a long term capability. This expanded capacity shall enable surge production of parenteral drug product capacity, to support the US Government's COVID-19 response and future pandemic or other critical situations. The recipient shall undertake all necessary activities to build out and expand capacity at its domestic manufacturing facilities. 2. Manufacturing capacity expansion shall be for vaccine consumables products including, but not limited to: Cell Culture Media, Bioreactors and Mixers Bags, Single Use Consumables 3. Manufacturing capacity expansion shall be capable of supporting projected 3rd party demand for consumables products from current BARDA sponsored COVID-19 vaccine developers through 2022, to specifically include the current surge requirement for the US domestic response to COVID-19. 4. The recipient shall ensure compliance with all Federal safety and health regulations and ensure Food and Drug Administration (FDA) approval upon completion of the effort for all of the new capacity. BARDA will support the recipient's requests for assistance in navigating and streamlining federal requirements to the maximum practical extent.

How to submit a preproposal. Interested parties should submit preproposals in accordance with Section III.F. and IV.C. Preproposals shall include technical details describing the type and amount of capacity increase envisioned, timeline to achieve that increase, a rough order of magnitude cost to achieve the increase, and the degree of cost sharing expected from the US Government.

Prototype development of a COVID-19 Pandemic Therapeutic Rapid Advanced Research and Development (ARD) to Large Scale Manufacturing.

Department of the Army W911QY-20-S-0019 28-Feb-2021 Not Specified

Contact Name Lawrence E. Mize
Contact Telephone 301-619-9813
Contact Email lawrence.e.mize.civ@mail.mil
Sponsor Website
Program URL Link to program URL
Deadline Dates (ALL) 28-Feb-2021

Prototype development of a COVID-19 Pandemic Therapeutic Rapid Advanced Research and Development (ARD) to Large Scale Manufacturing. This Prototype project is a combination of an agile development activity, design, and demonstration of the technical and
operational utility of a product to move forward to FDA licensure/approval. In accordance with Section III.F of announcement MCS BAA-17-01, the Government is hereby requesting formal submission of preproposals to execute a formal agreement under 10 USC 2371(b), Other Transaction Authority (OTA) for the prototype project described above: Upon receipt of a preproposal submitted in response to this RPP, the next steps are as follows: The Government will evaluate the preproposal. Discussions among the parties, whether verbally or in writing, will occur as appropriate. The Government may request a full proposal from the offeror. Additional discussions will occur as necessary. Award may be made after evaluation and selection of a successful proposal. (Note: Awards are dependent upon the availability of funds.) This Request for Project Proposal (RPP) is issued to request project proposals in compliance with USC 2371(b), and is being issued for planning purposes only. It is not to be construed as a commitment by the Government to award an agreement, nor will the Government pay for the information solicited. Specific requirements are identified in the Project Description/Statement of Objectives below. Due date: The date and time set for submission of preproposals is shown above. Preproposals received after the set time will not be considered unless the Government, at any time, elects to allot further time for proposal submissions. Preproposals shall be sent by email to: lawrence.e.mize.civ@mail.mil The Government will review/evaluate the submitted preproposals and if there is Government interest, the Agreements Officer may issue a request for full proposal (RFFP) in response to this RPP. The Government may award an agreement based on the proposal submission, or may require submission of additional details. The award of Prototype agreements shall be for the development of prototypes in accordance with 10 U.S.C. 2371b for projects that are directly relevant to enhancing the mission effectiveness of military personnel and the supporting platforms, systems, components, or materials proposed to be acquired or developed by the Department of Defense, or to improvement of platforms, systems, components, or materials in use by the Armed Forces. A prototype project can generally be described as a preliminary pilot, test, evaluation, demonstration, or agile development activity used to evaluate the technical or manufacturing feasibility or military utility of a particular technology, process, concept, end item, effect, or other discrete feature. Only a warranted Agreements Officer may obligate the U.S. Government to the expenditure of funds for awards under this Announcement. Evaluation will be performed by JPEO-CBRND and HHS-ASPR-BARDA personnel, other Federal Agency Representatives, outside scientists with diverse expertise, clinicians, consumers, or combinations thereof based on evaluation and selection of the best preproposal submission, and/or subsequent full proposal submission. After evaluation and selection, an award will be made to the successful offeror(s). Subsequent awards depend upon the availability of funds and fulfillment of requirements and priorities determined to
exist at the time of award. In some cases, funding priorities may change as certain scientific tasks are addressed and new mission assignments arise. Award may also be dependent upon demonstration by the offeror that they have adequately addressed the requirements. The U.S. Government does not fund preparation of proposals or support work efforts or tasks that are inferred from discussions with technical project officers. The Offeror will not be reimbursed for any costs incurred prior to the effective date of the agreement. There are certain post-employment restrictions on former Federal officers and employees as defined in 18 USC 207 and FAR 3.104-4(c). If an offeror believes a post-employment restriction or conflict of interest exists, notification should be sent to the Agreements Officer prior to initiating efforts on a full proposal. The Freedom of Information Act (FOIA) (5 USC 552) provides a statutory basis for public access to official U.S. Government records. “Records” are defined to include documentation received by the U.S. Government in connection with the transaction of public business. Certain types of information submitted to the Government in a process having the potential for award of an OT are exempt from disclosure requirements of FOIA for a period of five (5) years from the date the Government receives the information. The types of information listed above may continue to be exempted, in whole or in part, from disclosure after the expiration of the five (5) year period if it falls within an exemption to the FOIA such as trade secrets and commercial or financial information obtained from a person and privileged or confidential. Offerors should mark business plans and technical information that are to be protected for five years from FOIA disclosure with a legend identifying the documents as being submitted on a confidential basis. The Government is prohibited from soliciting and awarding actions to awardees that have engaged or are suspected to have engaged in criminal, fraudulent, or seriously improper conduct. Prospective awardees shall complete electronic annual representations and certifications at https://beta.sam.gov/. By submission of an offer, the Offeror acknowledges the requirement that prospective awardees MUST be registered in the System for Award Management (SAM) database prior to submitting an invoice and through final payment of any contract resulting from this RPP. Offerors that are not registered should consider applying for registration immediately upon receipt of this solicitation. To remain registered in the SAM database after the initial registration, the Offeror is required to review and update on an annual basis from the date of initial registration (or subsequent updates) its information in the SAM database to ensure it is current, accurate and complete. Data submitted that cannot be disclosed to the public for any purpose, or used by the Government except for evaluation purposes, shall be marked on the title page with the below legend and mark each data sheet as follows: TITLE PAGE LEGEND: This Proposal includes data that shall not be disclosed outside the Government and shall not be duplicated, used, or disclosed--in whole or in part--for any purpose other than to evaluate this Proposal. If, however, an agreement is awarded as a result of--or in connection
with— the submission of this data, the Government shall have the right to duplicate, use, or disclose the data to the extent provided in the resulting award. This restriction does not limit the Government's right to use information contained in this data if it is obtained from another source without restriction. The data subject to this restriction are contained in sheets [insert numbers or other identification of sheets]; DATA SHEET MARKING: Mark each sheet of data it wishes to restrict with the following legend: Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this proposal. Questions regarding this announcement may be submitted by email to lawrence.e.mize.civ@mail.mil within 2 days of the closing date. In accordance with 10 U.S.C. § 2371b(f), the Government may award a follow-on production contract or Other Transaction (OT) for any OT awarded under this BAA if: (1) that participant in the OT, or a recognized successor in interest to the OT, successfully completed the entire prototype project provided for in the OT, as modified; and (2) the OT provides for the award of a follow-on production contract or OT to the participant, or a recognized successor in interest to the OT. Follow-on production is anticipated to 800,000 treatments per quarter for up to 18 months. Proposals Brochures or other descriptions of general organizational or individual capabilities will not be accepted as a preproposal. All preproposals will be assigned an identification number and an email will acknowledge receipt of a proposal. Generally, the Project Manager of the submitting organization should receive a decision letter or email upon completion of the evaluation. Administration: The Government will retain comments and information received in response to this RPP. Do not use Government security classification markings. All written responses must be received by midnight of the due date. Submission should be identified with a Subject Line of Responding Organization and RPP Title. Material that is advertisement only in nature is not desired. Requirements: See Attached Project Description Submissions: Preproposals should be limited to six pages (including cover sheet), and include a description of the relevant technology including supporting data, the scope of the proposed effort including a high-level Work Breakdown Structure (WBS), and a description of the proposer’s research, development, manufacturing, past performance, or other special qualifications. The preproposal must also include an anticipated rough order of magnitude (ROM) cost for the efforts described in the preproposal, including a price per dose for both the manufacturing scale quantity and the follow-on production quantity. Preproposals shall be submitted to the following email address: Lawrence.e.mize.civ@mail.mil. PROJECT DESCRIPTION/STATEMENT OF OBJECTIVES 2.1 OBJECTIVE AREA –Treatment – COVID-19 Pandemic Therapeutic Rapid Advanced Research and Development (ARD) to Large Scale Manufacturing 2.1.1 DESCRIPTION/OBJECTIVE OF THE PROJECT: The Department of Defense and Department of Health and Human Services (HHS), seeks Offerors to perform at-scale prototype manufacturing and fill-finish of Coronavirus Disease 2019
(COVID-19) Medical Countermeasures (MCM) currently in advanced development, in order to ensure nationwide access. An outbreak of respiratory disease caused by a novel coronavirus, was first detected in China and has now spread worldwide, including the United States. The virus has been named Severe Acute Respiratory Disease Coronavirus-2 (SARS-CoV-2), and causes COVID-19. On January 30, 2020, the International Health Regulations Emergency Committee of the World Health Organization (WHO), declared the outbreak a “Public Health Emergency of International Concern” (PHEIC). On January 31, the United States Department of Health and Human Services Secretary, Alex M. Azar II, declared a Public Health Emergency (PHE) for the United States to aid the nation’s healthcare community in responding to COVID-19. On March 11, WHO publicly characterized COVID-19 as a pandemic. On March 13, the President of the United States declared the COVID-19 outbreak a national emergency. It is critical for the sponsors of COVID-19 therapeutic candidates to initiate at-scale prototype manufacturing to demonstrate the target population capability. As such, the USG will support at-scale manufacturing (through packaging and release testing) of selected MCMs, to ensure timely availability to the US population when needed. 2.1.2 STATEMENT OF OBJECTIVES (SOO): 1) Project Objectives: The objective of this prototype project is to initiate an advanced development SARS-CoV-2 MCM prototype for clinical/non-clinical development and/or manufacturing scale-up to demonstrate the capability to support sustained large scale manufacturing necessary to meet surge requirements with little advance notification, under the conditions for which the MCM is being developed. Candidate MCMs will either be direct acting antivirals or host directed therapeutics, which indirectly inhibit the coronavirus lifecycle. Prior in vitro and in vivo demonstration of efficacy against SARS-CoV-2 is required. Candidate MCMs shall have at minimum, capability of obtaining Emergency Use Authorization (EUA) and/or a reasonable chance of moving to Phase 3 clinical trials by 4Q 2020 including all development plans and efforts, manufacturing, all done in support of the goal of achieving FDA approval/licensure in 2021. Offerors must have started or have completed a Phase 1 clinical study no later than August 31, 2020. The Offeror will need to demonstrate large scale manufacturing capability by completing the manufacture, release, stockpiling and distribution of up to 100,000 drug product treatment courses by December 31, 2020. Fill and release of drug product should be included within the proposed scope but can be completed in Q1/Q2 2021. A treatment course is defined by the highest dose proposed for Phase 2 clinical trials. Optional line items associated with full scale Follow-On production quantities to treat up to 800,000 people per quarter may be included in the negotiated project agreement. These option line items may be exercised at the Government's sole discretion in accordance with paragraph 2.1.4.3. 2) Performance Objectives (Required Results): The U.S. Government, in support of Operation Warp Speed, seeks Offerors to perform at-scale prototype manufacturing and fill-
finish of a SARS-CoV-2 MCM. Initially at the minimum, fill/finish manufacturing shall take place in a US-based facility. Manufacturing shall occur using cGMP validated manufacturing processes for bulk drug substance and fill and finished drug product. The ramp-up capacity provides up to 100,000 treatment courses for a targeted US population by December 31, 2020, to treat the US population indicated in the Offeror’s target population. A treatment course is defined by the highest dose proposed for Phase 2 clinical trials. A minimum quantity is not defined; however, the intent is “Large Scale production capability in a short period of time with little to no advance notice under the conditions for which the MCM is required”. Demonstration of efficacy should be included in the performance plan with support for platform clinical trial conduct. The Offeror’s proposal should include a validation plan and associated timelines. The project shall be accomplished using aggressive risk management and taking advantage of any regulatory flexibilities. A description of the manufacturing facility, quality assurance, and regulatory acceptance, including quality systems and regulatory milestones towards facility approval, is required. To assist with facility assessment, the chemical synthesis and process description should be included. It is desired that the drug substance manufacturing be US based. If this is not initially possible, a mitigation strategy including a reasonable timeline is required for transfer to the future at-scale drug substance US based manufacturing facility. The supply of and manufacture of regulatory starting materials including key chemical reagents and raw materials must be sustainable and desirably US sourced. If foreign sourced a mitigation plan is needed. 3) Regulatory Objectives: Candidate MCMs shall have at a minimum, capability of obtaining Emergency Use Authorization (EUA) and/or a reasonable chance of moving to Phase 3 clinical trials by 4Q 2020 including all development plans and efforts, manufacturing, all done in support of the goal of achieving FDA approval/licensure in 2021. 4) Project Management Objectives: Mandatory reporting requirements are described in the base agreement: Monthly progress reports should include both technical and financial status and expenditure forecast; final prototype project report; patents reports, work breakdown structure; integrated master schedule; regulatory documents, including communications with the FDA, all submissions, and the PL 115-92 Sponsor Authorization Letter. Project management oversight will be comprised of an Agreements Officer’s Representative (AOR) and USG Project Coordination Team (PCT), which will perform ongoing technical reviews and approvals of milestones. The Offeror shall invite the government to attend all FDA meetings with regard to this project. 5) Logistics Objectives: The USG seeks at-scale prototype manufacturing and fill-finish of a SARS-CoV-2 MCMs currently in advanced development. Production shall occur using an established manufacturing process for bulk drug substance and fill and finished drug product, with a plan that provides up to 100,000 treatment courses of drug product for a targeted US population by December 31, 2020. A treatment course is defined by
the highest dose proposed for Phase 2 trials. Initially it may be considered acceptable for the drug substance and the 100,000 treatment courses to manufacture at a smaller scale provided that the scale is of sufficient manufacturing scale to properly demonstrate the process. This scale must use the same synthesis, targeted, scalable, validated process, possessing the needed potential ramp-up capacity for the at-scale manufacturing. The at-scale development and manufacturing must occur in parallel. Once finished drug product is accepted by the US Government, product will be stored and distributed by the Offeror. 6) Performance Requirements: Manufacture of the therapeutic product shall occur using an established manufacturing process for bulk drug substance and fill and finished drug product, with a ramp-up capacity plan that provides enough doses to meet the desired treatment course. The Offeror’s proposal should include a validation plan and associated timelines. The project shall be accomplished using aggressive risk management and taking advantage of any regulatory flexibilities. A description of the manufacturing facility quality assurance and regulatory acceptance, including quality systems and regulatory milestones towards facility approval is required. 7) Operational Constraints/Limitations/Restrictions: Fill/finish manufacturing operations shall be based in the US. 2.1.3 PERIOD AND PLACE OF PERFORMANCE: The anticipated Period of Performance for this effort is up to two (2) years from the date of award (including options). Specific dates to be negotiated. It is anticipated that the primary place of performance will be the contractors’ or subcontractors’ facilities. However, this aspect can be negotiated as part of each Offerors’ submission. 2.1.4 DELIVERABLES: 2.1.4.1 DATA DELIVERABLE(S): Data Deliverables required include: • Meeting minutes from all scheduled and ad-hoc meetings with the Program Office and AOR. • Monthly financial reports required for invoice approval. • All FDA communications, including minutes and submissions. • Detailed Work Breakdown Structure that enables the proposed Statement of Work. • The Offeror shall have a comprehensive Supply Chain Resiliency Program that provides for identification and reporting of critical components associated with the secure supply of drug substance, drug product, and work-in-process through to finished goods. • FDA Form 483 and the Establishment Inspection Report (EIR) if applicable • Bi-Weekly Performance meeting agendas, meeting minutes, and briefings • All required reports and documents (in contractor format) set forth in Addendum 1 to this Project Description Note: Technical data deliverables described herein shall be delivered to the Government with a minimum of Government Purpose Rights 2.1.4.2 PROTOTYPE DELIVERABLE(S): The prototype Deliverable includes the fill/finished therapeutic drug product authorized for use by the FDA, and/or demonstrated manufacturing capability meeting the performance objectives. Drug product must be delivered by December 31, 2020, in the US; drug product will not be accepted until it is physically located in the US. 2.1.4.3 Follow-on Production: In
accordance with 10 U.S.C. 2371b(f), and upon a determination that the prototype project for this transaction has been successfully completed, any competitively awarded prototype OTA as a result of this RPP may result in the award of a follow-on production contract or transaction without the use of competitive procedures. The Government intends to purchase sufficient quantities to treat an estimated 800,000 people per quarter with the selected MCM therapeutic for the duration of 2021. The Offeror’s proposal shall include production option(s) to purchase the fill/finished drug product, based on maximum production capability, providing quantity per month, price per dose and per gram, inclusive of all direct and indirect costs, storage, and distribution to US Government designated facilities. The manufactured prototype will be successful if: • The prototype is safe and effective, as agreed to by the FDA either by licensure or under an EUA or, • The Offeror demonstrates capability of delivering up to 100,000 treatment courses of drug product for a targeted population by December 31, 2020 in the US. 2.1.5 SPECIAL REQUIREMENTS: 2.1.5.1 Export Control: Export Controls shall be in accordance with the Base Agreement. 2.1.5.2 Security and Classified Data: This project is Unclassified. 2.1.5.3 Acceptance of Deliverables: The Government will provide acceptance of all data deliverables within ten (10) calendar days of delivery. The Government will provide acceptance of all therapeutic prototype deliverables within thirty (30) calendar days of delivery and physical delivery to US soil. 2.1.5.4 Travel: The following travel situations may be approved by the Government upon request: • Travel for Face-to-face meetings with Government personnel and/or sub-contractors. • Travel to provide oversight, audits, and/or data reviews with sub-contractors. • Travel for Program review meetings or Integrated Product Team (IPT) meetings, as requested by the Government. • Travel to complete in-person FDA requested meetings. Additional non-directed travel, necessary for the completion of the contracted work, may be permitted. The Offeror shall provide a breakout of expected travel in their proposal. 2.1.6 GOVERNMENT FURNISHED PROPERTY: Government Furnished Equipment, Contractor Acquired Government Furnished Property, and Contractor Acquired Government Owned Property are subject to negotiations during the award process. The contractor should identify necessary equipment and property in white paper submissions to this RPP. 2.1.7 FUNDING CONFIDENCE LEVEL: CL-1 Highly Confident funds will be available. 2.1.8 AGREEMENTS OFFICER’S REPRESENTATIVE (AOR): Name: Kristen Herring Telephone: 202-260-1388 E-mail: kristen.herring@hhs.gov Office Symbol: HHS/ASPR/BARDA 2.1.8.1 ALTERNATE AOR: Name: Nellie Byun Telephone: 202-774-2303 E-mail: Nellie.byun@hhs.gov Office Symbol: HHS/ASPR/BARDA 2.1.9 Requiring Activity: Joint mission between the Department of Health and Human Services and Department of Defense to combat COVID-19
**Medical Reserve Corps Small Grant Program**

**Assistant Secretary for Preparedness and Response/DHHS**

**EP-HIT-20-001** 21-Sep-2020 Not Specified

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Moji Obiako</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>206-615-2025</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:moji.obiako@hhs.gov">moji.obiako@hhs.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to sponsor website</td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>21-Sep-2020</td>
</tr>
</tbody>
</table>

**Synopsis**

The Medical Reserve Corps (MRC) is a national network of 175,000 volunteers organized into approximately 850 local community-based groups which are committed to improving local emergency response capabilities, reducing vulnerabilities, and building community preparedness and resilience. MRC units organize and utilize local volunteers who want to donate their time and expertise to prepare for and respond to emergencies and to support steady-state preparedness initiatives. MRC volunteers include medical and public health professionals as well as other community members without healthcare backgrounds. MRC units bolster their community’s preparedness and emergency response infrastructures by providing supplemental personnel when needed, thus making those local communities less likely to be reliant on state and national resources. The majority of MRC units are sponsored by local health departments; other types of sponsoring organizations include emergency management agencies, local non-profits, and universities.

SMARTS™ funding alerts are a service of InfoEd Global's SPINTM funding opportunities.

---

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE. This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

Visit the Research Portal Getting Started page and enter email address under Research Listserv to update your subscription preferences at any time within the MSHS firewall.